Friday, 15 Feb 2019

You are here

FDA Approves Biosimilar Rituximab for NHL, not RA

The U.S. Food and Drug Administration on Wednesday approved Celltrion biosimilar of rituximab called Truxima; previously called CT-P10, now generically labeled as rituximab-abbs.  This is the first biosimilar to the Rituxan currently approved to treat non-Hodgkin’s lymphoma.  Truxima is not approved for use in rheumatoid arthritis, vasculitis, pemphigus vulgaris or chronic lymphocytic leukemia. See package insert here.

The approval was largely expected as the drug won unanimous backing from an FDA advisory panel in October 2018, which deemed it highly similar to Rituxan.  Biosimilarity was clinically established in trials of lymphoma patients and not in other clinical populations (eg, RA, GPA, etc).

Truxima’s label comes with the same boxed warning as Rituxan, noting fatal infusion reactions, hepatitis B reactivation, severe mucocutaneous reactions and progressive multifocal leukoencephalopathy (PML). 

Roche’s drug, approved in 1997, is marketed as Rituxan in the United States, Japan and Canada and as MabThera elsewhere.

Earlier this month, Novartis International AG said it would no longer pursue U.S. regulatory approval for its biosimilar of Rituxan after the FDA sought additional information to support the company’s application for the drug.

Celltrion entered into a partnership with Teva Pharmaceutical Industries in 2016 to commercialize Truxima in United States and Canada.

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Stopping Biologics Before Joint Surgery: Is Earlier Better?

Withholding intravenous abatacept (Orencia) for longer than a month before hip or knee arthroplasty among patients with rheumatoid arthritis (RA) did not lower the risk for postoperative infection, a retrospective claims-based analysis found.

Biologic High Out of Pocket Costs for Medicare Patients

Specialty tier drugs, including biologics, accounts for nearly half of all medication spending by Medicare Part D patients. High out-of-pocket costs for these patients is a major concern. 

RheumNow Podcast – TNFs and the Inflammasome (1.25.19)

Dr Jack Cush reviews the news from the past week at RheumNow.com.

Smoking Doesn't Influence Rituximab Responses in Rheumatoid Arthritis

Alcohol, smoking and obesity have all been shown to influence the risk and activity of rheumatoid arthritis (RA) and may also influence response to therapy. This study assesssed whether smoking would influence response to rituximab (RTX) in RA. 

Anakinra for Acute Crystal-Induced Arthritis

A retrospective analysis of hospitalized patients who also had a gout and pseudogout attack shows that injections of anakinra (interleukin-1 receptor antagonist) were highly effective and safe in nearly three-quarters of patients.  

Through a medical records search they found 100 patients and 115 episodes between 2014-2017 who were treated with anakinra for crystal arthritis.